Propanc Biopharma (PPCB) News Today $3.12 +0.18 (+6.12%) As of 08/28/2025 04:00 PM Eastern Add Compare Share Share Headlines Stock AnalysisChartEarningsHeadlinesSEC FilingsShort InterestBuy This Stock PPCB Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 Time Period D. Boral Capital Acted as Lead Bookrunner to Propanc Biopharma, Inc. in Connection with its $4,000,000 UplistingAugust 28 at 8:23 PM | finanznachrichten.deD. Boral Capital Acted as Lead Bookrunner to Propanc Biopharma, Inc. (Nasdaq:PPCB) in Connection with its $4,000,000 UplistingAugust 28 at 8:23 PM | finance.yahoo.comPropanc Biopharma raises $4 million in Nasdaq debut, plans cancer trialsAugust 26 at 5:06 AM | investing.comPropanc Biopharma Provides Shareholder UpdateAugust 25, 2025 | globenewswire.comPropanc Biopharma, Inc.: Propanc Biopharma Announces Closing of Public Offering and Uplisting to NASDAQAugust 20, 2025 | finanznachrichten.dePropanc Biopharma Announces Closing of Public Offering and Uplisting to NASDAQAugust 19, 2025 | globenewswire.comWhy Propanc stock Is Tumbling In Premarket TodayAugust 19, 2025 | msn.comThe Next Wave of Cancer Innovation: How Breakthrough Therapies Are Redefining Treatment ParadigmsAugust 18, 2025 | theglobeandmail.comPropanc Biopharma IncAugust 17, 2025 | cnn.comPropanc Biopharma opens at $4.00 in Nasdaq uplistingAugust 15, 2025 | msn.comPropanc Biopharma, Inc.: Propanc Biopharma Announces Nasdaq Uplisting and Pricing of $4 Million Public OfferingAugust 15, 2025 | finanznachrichten.dePropanc Biopharma prices $4M stock offeringAugust 15, 2025 | msn.comPropanc Biopharma Announces Nasdaq Uplisting and Pricing of $4 Million Public OfferingAugust 14, 2025 | globenewswire.comPropanc Biopharma 1M share Secondary; price range $4.00-$6.00August 14, 2025 | msn.comPropanc Biopharma Appoints New Chief Financial OfficerAugust 14, 2025 | msn.comPropanc Biopharma Issues Promissory Note for CapitalJune 2, 2025 | tipranks.comPropanc Biopharma (OTCMKTS:PPCB) Stock Price Down 53.7% - Should You Sell?February 26, 2025 | marketbeat.comPropanc Biopharma (OTCMKTS:PPCB) Trading Up 108.3% - Still a Buy?January 30, 2025 | marketbeat.comPropanc Biopharma Inc (PPCB)August 21, 2024 | investing.comPropanc Biopharma Receives Notice of Allowance for "Proenzyme Composition" Patent in North AmericaAugust 14, 2024 | finance.yahoo.comVTXB Vortex Brands Co.May 29, 2024 | seekingalpha.comPropanc Biopharma, Inc. (PPCB)May 29, 2024 | finance.yahoo.comPropanc Biopharma Receives Certificate of Grant for "Composition of Proenzymes for Cancer Treatment" Patent from European Patent OfficeApril 16, 2024 | finance.yahoo.comPropanc Biopharma's CEO Shares Views on Revolutionizing Cancer Treatment: An Inside Look at Drug Development & Strategic FinancingApril 10, 2024 | stockhouse.comPropanc Biopharma’s CEO Shares Views on Revolutionizing Cancer Treatment: An Inside Look at Drug Development & Strategic FinancingApril 8, 2024 | finance.yahoo.comPropanc Biopharma to Host Corporate Update Call Highlighting Recent Progress and Positive Results from Compassionate Use StudyFebruary 22, 2024 | finance.yahoo.comPropanc Biopharma Receives Certificate of Grant for PRP Foundation Patent from Canadian Intellectual Property OfficeJanuary 16, 2024 | finance.yahoo.comPropanc Biopharma Engages Boutique Advisory Firm to Identify Strategic Investment OpportunitiesDecember 18, 2023 | finance.yahoo.comPropanc Biopharma’s Joint Research Partner Pushing Boundaries to Circumvent Chemotherapy Resistance Using PRPDecember 13, 2023 | finance.yahoo.comJames Nathanielsz, CEO of Propanc Biopharma, Inc., is Featured in an Interview With SmallCapsDailyDecember 12, 2023 | finance.yahoo.comPropanc Biopharma, Inc.: Propanc Biopharma Confirms PRP Enhances Chemosensitivity and Alters Tumor Microenvironment of Pancreatic Tumor CellsNovember 7, 2023 | finanznachrichten.dePropanc Biopharma Confirms PRP Enhances Chemosensitivity and Alters Tumor Microenvironment of Pancreatic Tumor CellsNovember 7, 2023 | finance.yahoo.comPropanc Biopharma Targets Site of First-In-Human Study for PRP at the Peter Mac Cancer Center, Melbourne, AustraliaAugust 15, 2023 | finance.yahoo.comPropanc Biopharma’s Clinical Candidate PRP Targeting Pancreatic Cancer Market Forecast to Reach $6.93 Billion by 2030July 26, 2023 | finance.yahoo.comPropanc Biopharma Peer Reviewed Scientific Article Reaches 3,000 ReadsJuly 13, 2023 | finance.yahoo.comPropanc Biopharma Produces Synthetic Recombinant Proenzymes for Cancer Therapy Targeting Advanced Solid TumorsJuly 5, 2023 | finance.yahoo.comPPCB - Propanc Biopharma, Inc.June 30, 2023 | sg.finance.yahoo.comPROPANC BIOPHARMA INC (PPCB) stock forecast and price targetJune 28, 2023 | finance.yahoo.comPropanc Biopharma’s Intellectual Property Portfolio Makes Important Advancements in EuropeMay 25, 2023 | finance.yahoo.comPropanc Biopharma’s Intellectual Property Portfolio Achieves Significant Milestones in North AmericaMay 23, 2023 | finance.yahoo.comPropanc Biopharma Announces Reverse Stock SplitMay 23, 2023 | finance.yahoo.comPropanc Biopharma Announces That PRP Suppresses TGF-β Pathway & Tumor Microenvironment in Pancreatic CancerMarch 28, 2023 | finance.yahoo.comPropanc Biopharma Confirms PRP Exerts Significant Effects Against Chemoresistant Pancreatic Tumor CellsMarch 16, 2023 | finance.yahoo.comXeris Biopharma Holdings Stock (NASDAQ:XERS), Analyst Ratings, Price Targets, PredictionsMarch 14, 2023 | benzinga.comPPCB Propanc Biopharma, Inc.February 23, 2023 | seekingalpha.comPropanc Biopharma’s Joint Researcher Presents at the 43rd Meeting of the European Organization of Research & Treatment of Cancer (EORTC)January 11, 2023 | finance.yahoo.comPropanc Biopharma, Inc.: Propanc Biopharma's Joint Researcher Receives Award at Doctoral Conference at the University of JaénDecember 17, 2022 | finanznachrichten.dePropanc Biopharma’s Joint Researcher Receives Award at Doctoral Conference at the University of JaénDecember 15, 2022 | finance.yahoo.comPropanc Biopharma Concludes PRP Could Become an Effective Chemosensitizer Agent Against Pancreatic CancerNovember 30, 2022 | finance.yahoo.comPropanc Biopharma’s CSO Predicts PRP Could Enhance Therapeutic Effects of Immune Checkpoint Therapy for Pancreatic CancerNovember 15, 2022 | finance.yahoo.com Get Propanc Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for PPCB and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. PPCB Media Mentions By Week PPCB Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. PPCB News Sentiment▼-0.331.03▲Average Medical News Sentiment PPCB News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. PPCB Articles This Week▼40▲PPCB Articles Average Week Get the Latest News and Ratings for PPCB and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Propanc Biopharma and its competitors. Sign Up View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies Trevena News Vincerx Pharma News Capstone News Omega Therapeutics News NuCana News Hero Technologies News Smart for Life News Virpax Pharmaceuticals News HST Global News Wellness Center Usa News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (OTCMKTS:PPCB) was last updated on 8/29/2025 by MarketBeat.com Staff From Our PartnersMusk’s Project Colossus could mint millionairesI predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Propanc Biopharma Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Propanc Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access